Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.60
−$0.30 · -2.33%
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Previous close
$12.60
−$0.30 · -2.33%
Regular session · ET · Market data may be delayed.
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Day range
Current $12.60
52-week range
Current $12.60
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
66
Bullish
Risk
66
High Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Day range
Current $12.60
52-week range
Current $12.60
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 16.68K USD |
| Cost of goods sold | — | — | 10.44M USD | — | 5.85M USD |
| Gross profit | — | — | −10.44M USD | — | −5.84M USD |
| Research and development | 33.38M USD | 10.64M USD | 7.88M USD | 16.09B USD | 4.95M USD |
| Selling, general, and administrative | 6.79M USD | 6.19M USD | 6.38M USD | 7.29B USD | 3.31M USD |
| Operating expenses | 40.17M USD | 16.83M USD | 8.45M USD | 23.38B USD | 4.63M USD |
| Interest income | — | — | — | — | 4.73K USD |
| Interest expense | — | 76.78K USD | 201.39K USD | 282.06M USD | 416.29K USD |
| Depreciation and amortization | — | — | 28.04K USD | — | 45.83K USD |
| Operating income | −40.17M USD | −16.83M USD | −18.9M USD | −23.38B USD | −10.57M USD |
| Net income | −39.72M USD | 2.78M USD | −17.51M USD | −18.06B USD | −11.98M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
